The Ethical Medicines Industry Group (EMIG) has surveyed its members to understand the pressures on various aspects of medicine production and supply during the coronavirus pandemic.
The EMIG survey was detailed, and captures issues across the supply chain, procurement and commissioning. Any readers interested in learning more about the survey or EMIG should contact EMIG here.
The main findings from the survey were that industry expects an increase in demand, requiring bigger stocks and larger production. Delays have so far been identified in 48% of respondents’ supply chains, so manufacturers will need to adapt to potential disruption; many are reviewing their supply chains. 45% of respondents identified out-of-stock events as a future concern.
EMIG also found that most companies had not yet reported concerns to the Department of Health and Social Care (DHSC), meaning most companies are relying on their own resourcefulness to overcome their challenges.
Companies indicated they would appreciate more information from Government, for example one response said:
“Air companies are facing a huge cashflow problem which is forcing them to ground their airplanes. That is creating a huge constraint in cargo availability. What can the Government do to support pharma companies to mitigate this?”
For access to the full survey results, contact Leslie Galloway, Chair of EMIG, here.